2841-80-7

Usage

Uses

Used in Pharmaceutical Industry:
(2Z)-2-(hydroxymethylidene)cholest-4-en-3-one is used as an intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting hormonal imbalances and related conditions. Its unique structure allows for the development of drugs with specific therapeutic properties.
Used in Chemical Industry:
In the chemical industry, (2Z)-2-(hydroxymethylidene)cholest-4-en-3-one serves as a key building block for the production of various steroidal compounds and derivatives. Its versatility in chemical reactions makes it a valuable component in the synthesis of complex organic molecules with diverse applications.

Upstream product

• 601-57-0 Cholest-4-en-3-one 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 1079130-02-1 C₄₀H₅₃N₃O₃ 
• 1079130-08-7 C₃₉H₅₀ClN₃O₂ 
• 1079130-04-3 C₄₁H₅₅N₃O₂ 
• 1079130-01-0 C₄₀H₅₃N₃O₂ 
• 1079130-27-0 C₄₀H₅₃N₃O₂ 
• 1079130-25-8 C₃₈H₄₈ClN₃O₂ 
• 1079130-00-9 C₃₉H₅₁N₃O₂ 
• 1079130-18-9 C₃₈H₄₉N₃O₂ 
• 1079130-07-6 C₃₉H₅₀FN₃O₂ 
• 1079130-30-5 C₄₄H₅₃N₃O₂ 
• 1079130-10-1 C₃₉H₅₀BrN₃O₂ 
• 1079130-39-4 C₄₄H₅₂ClN₃O₂ 
• 1079130-36-1 C₄₆H₅₇N₃O₂ 
• 1079130-28-1 C₃₉H₅₁N₃O₂ 

Relevant academic research and scientific papers

Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin-cholestane hybrid compounds

Novel deazaflavin-cholestane hybrid compounds, 3′,8′-disubstituted-5′-deazacholest-2,4-dieno[2,3-g]pteridine-2′,4′(3′H,8′H)-diones, have been synthesized by condensation reaction between 6-(monosubstituted amino)-pyrimidin-2,4(1H,3H)-diones and 2-hydroxymethylenecholest-4-en-3-one in presence of p-toluenesulfonic acid monohydrate and diphenyl ether. The antitumor activities against human tumor cell lines (CCRF-HSB-2 and KB cells) have been investigated in vitro, and many of these compounds showed promising antitumor activities. Furthermore, molecular docking study using LigandFit within the software package Discovery Studio 1.7 was done for lead optimization of these compounds as potential PTK inhibitors. In general, all of the synthesized steroid-hybrid compounds showed good binding affinities into PTK (PDB code: 1t46).